Medistat

Executive Summary

Medistat is an Israeli-based contract research organization (CRO) specializing in biostatistics, data management, and clinical trial analytics. Founded in 2020, the company serves pharmaceutical and biotech sponsors by leveraging advanced statistical methods and data science platforms to optimize trial design, execution, and regulatory submissions. With a team of 10–50 employees, Medistat focuses on delivering high-quality, compliant data solutions that accelerate drug development timelines across therapeutic areas. Its expertise in data integrity and regulatory compliance positions it as a reliable partner for sponsors seeking to improve clinical trial efficiency and reduce time-to-market. The company operates in a competitive CRO landscape but differentiates itself through specialized statistical rigor and a focus on data-driven insights. Medistat's relatively small size allows for agile, customized service delivery, while its location in Israel provides access to a strong talent pool in data science and life sciences. As the clinical trial market continues to expand, especially with increasing complexity in trial designs and regulatory requirements, Medistat is well-positioned to capture opportunities from mid-sized biotechs and large pharma seeking outsourced biostatistics and data management. However, the company's limited scale and track record may pose challenges in winning large, long-term contracts against established global CROs.

Upcoming Catalysts (preview)

• Q4 2026Major pharma partnership or contract win40% success
• Q2 2027Launch of AI/ML-driven analytics platform50% success
• Q1 2027Expansion into European or North American market35% success